This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Molecular Diagnostics to Aid Hologic's (HOLX) Q3 Earnings
by Zacks Equity Research
Strength in the Panther system and increasing utilization of Aptima women's health assays will boost Hologic's (HOLX) molecular diagnostics in Q3.
Can Strategic Alliances Aid LabCorp's (LH) Q2 Earnings?
by Zacks Equity Research
LabCorp (LH) is expected to gain traction from a solid LabCorp Diagnostics segment in Q2, courtesy of a favorable price, mix, tuck-in acquisitions and organic volume.
Is LabCorp (LH) a Great Stock for Value Investors?
by Zacks Equity Research
Let???s see if LabCorp (LH) stock is a good choice for value-oriented investors right now from multiple angles.
Stock Market News For Jul 2, 2018
by Zacks Equity Research
Markets closed higher on Friday, the last trading session of the first half of the year, as energy stocks rallied.
LabCorp, Philips Tie Up to Advance in Digital Pathology
by Zacks Equity Research
Through the latest collaboration, LabCorp (LH) aims at strengthening its hold inthe high potential digital pathology market.
Why You Should Retain Quest Diagnostics in Your Portfolio
by Zacks Equity Research
Quest Diagnostics (DGX) reveals both sides of the same coin, reflecting its bleak aspects plaguing the stock as well as projecting its brighter side to denote a near-term rebound.
Why Is Laboratory of America Holdings (LH) Up 1.7% Since Its Last Earnings Report?
by Zacks Equity Research
Laboratory of America Holdings (LH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
LabCorp (LH) Beats on Earnings & Revenues in Q1
by Zacks Equity Research
Here we have highlighted some of the key details from the just-released earnings report of Laboratory Corp. of America Holdings (LH).
LabCorp Forms Lab-Alliance With Kentucky-Based Health Firm
by Zacks Equity Research
The multi-year, comprehensive laboratory deal to help LabCorp (LH) provide high-quality, high-value and standardized laboratory diagnostics for Appalachian Regional Healthcare.
Is Laboratory Corporation (LH) a Great Stock for Value Investors?
by Zacks Equity Research
Is Laboratory Corporation (LH) a great pick from the value investor's perspective right now? Read on to know more.
LabCorp (LH) Up 1.1% Since Earnings Report: Can It Continue?
by Zacks Equity Research
LabCorp (LH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
LabCorp (LH) Tops Q4 Earnings & Misses Revenue Estimates
by Zacks Equity Research
LabCorp (LH) witnessed year over year growth in net revenue on the back of both LabCorp Diagnostics and Covance Drug Development segment in Q4.
LabCorp (LH) Beats on Q3 Earnings & Revenue Estimates
by Zacks Equity Research
LabCorp (LH) rides high on both LabCorp Diagnostics segment and Covance Drug Development segment in Q3.
What's in the Cards for LabCorp (LH) This Earnings Season?
by Zacks Equity Research
LabCorp (LH) might gain from continued growth in its companion diagnostics portfolio in Q3.
Should Value Investors Pick Laboratory Corporation (LH) Stock?
by Zacks Equity Research
Is Laboratory Corporation (LH) a great pick from the value investor's perspective right now? Read on to know more.
LabCorp Completes $1.2-Billion Chiltern Buyout, Boosts CRO
by Zacks Equity Research
In line with its inorganic growth strategy, LabCorp's (LH) latest Chiltern buyout is aimed at promoting the CRO business.
LabCorp (LH) Beats on Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Laboratory Corp. of America Holdings (LH) rides high on its Diagnostics business Q2. The raised outlook buoys optimism.
LabCorp (LH) Tops Q1 Earnings, Misses Revenue Estimate
by Urmimala Biswas
LabCorp has a Zacks Rank #4(Sell) but that could change following its first quarter 2017 earnings report which has just released.
Is Laboratory Corp. a Suitable Stock For Value Investors?
by Zacks Equity Research
Let's put Laboratory Corporation Of America Holdings (LH) stock into this equation and find out if it is a good choice for value-oriented investors right now.
LabCorp (LH) Up 3.6% Since Earnings Report: Can It Continue?
by Zacks Equity Research
LabCorp (LH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
LabCorp (LH) Beats on Q4 Earnings & Revenue Estimates
by Zacks Equity Research
LabCorp posted fourth quarter 2016 results with both earnings and revenues beating the Zacks Consensus Estimate.
MedTech Stocks' Q4 Earnings on Feb 16: LH, WST and MDRX
by Zacks Equity Research
Let's take a look at the major MedTech stocks slated to release their fourth-quarter 2016 numbers on Feb 16.
Lots Happening in MedTech: Should You Buy These Stocks?
by Zacks Equity Research
We have noticed a substantial transformation in the U.S. medical device market of late and it is important for market participants to adapt. We have hit upon3 major evolving trends in this sector.
3 Stocks That Beat Earnings and Raised This Week
by Brian Bolan
The beat and raise is music to the ears of the aggressive growth investor.